Trial Profile
A Phase 1/2 Open-Label, Safety, Pharmacokinetic, Pharmacodynamic and Efficacy Study of RX-3117 in Combination With Abraxane in Subjects With Metastatic Pancreatic Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Dec 2023
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Roducitabine (Primary) ; Gemcitabine
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Processa Pharmaceuticals
- 12 Aug 2021 Results published in the Investigational New Drugs
- 03 Jan 2020 Status changed from active, no longer recruiting to completed.
- 07 Aug 2019 According to a Rexahn Pharmaceuticals media release, final data from the trial is expected in 2020.